Navigation Links
Charting the Biosimilar and Biobetter Development Pipeline
Date:9/20/2012

Biosimilar and Biobetter Development Pipeline , you'll find details of currently marketed biosimilar and biobetter drugs, and all biosimilar and biobetter drugs known to be in clinical development.

 

Through more than 60 intuitive tables and charts, you will receive unique insights into high-level trends and significant developments, and can easily drill down to details of a specific product or therapeutic area.

 

Need to know when Drug X will expire? Expiration dates for reference products draw on analysis of products, active agents, and manufacturing processes to go far beyond the Orange Book.

 

Need to know who is developing biobetters for interferons? Access a complete list with generic and candidate names, developers, reference products, and earliest possible EU/US launch dates.

 

The report's author has also included concise commentary throughout, providing valuable context and key insights.

 

For a complete guide to biosimilars at your fingertips, download Charting the Biosimilar and Biobetter Development Pipeline today.

 

 

 

Key Report Features

More than 60 exclusive tables and charts, offering a complete and illuminating view of the biosimilar pipeline

Up-to-the-minute details of ALL biosimilars/biobetters known to be in development in US and EU markets, with their development status and earliest potential launch dates

Information on international biogenerics that may seek approval as biosimilars/biobetters in US and EU markets

Comprehensive list of reference products, with key sales data and expected patent expiration dates

Detailed analysis of the biosimilar pipeline and market by reference products, therapeutic area, drug class, and compound class

Reports showing the most active companies, regions, and countries

Insights into areas of most intense competition
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
2. Artificial womb unlocks secrets of early embryo development
3. REST is crucial for the timing of brain development
4. Embryonic development protein active in cancer growth
5. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
6. Stomata development in plants unraveled -- a valuable discovery for environmental research
7. Promising developments in early diagnosis and treatment of mesothelioma
8. Europe meets to discuss progress in energy research and development
9. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
10. New genes contributing to autism and related neurodevelopmental disorders uncovered
11. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2014)... A 20-year assessment of Nicaragua,s legal, artisanal green sea ... overall catch rates of turtles in what may have ... the Wildlife Conservation Society and University of Florida. , ... than 170,000 green turtles were killed between 1991 and ...
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... as Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) is ... weakness and atrophy. Researchers have long considered it to be ... in the spinal cord and brainstem that control muscle movement. ... 16, 2014 online issue of Neuron , a team ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2
... heart disease, neurological disorders and other degenerative conditions, some scientists ... are finding you,re not a creature of either genetics or ... approach to health. The new field of "epigenetics" is ... a certain genetic code at conception. But, the choice of ...
... A team of scientists working at beamline 9.0.1 of ... of Energy,s Lawrence Berkeley National Laboratory has used x-ray ... achieving the highest resolution11 to 13 nanometers (billionths of ... Their success indicates that full 3-D tomography of whole ...
... team is studying whether running the Yuma Desalting Plant will ... the Colorado River Delta. The cienega, a 15,000-acre wetland, ... stopover for birds migrating north and south along the Pacific ... to begin its latest trial run May 3. "The ...
Cached Biology News:'Epigenetic' concepts offer new approach to degenerative disease 2'Epigenetic' concepts offer new approach to degenerative disease 3Lensless imaging of whole biological cells with soft X-rays 2Lensless imaging of whole biological cells with soft X-rays 3Lensless imaging of whole biological cells with soft X-rays 4Researchers study effect of yuma desalting plant on Cienega de Santa Clara 2Researchers study effect of yuma desalting plant on Cienega de Santa Clara 3
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... in Australia through ... retail pharmacies nationwide, TAMPA, Fla., ... leader in pharmacy-based patient care services and,healthlinks.net, a subsidiary of ... a definitive technology licensing and business,consulting agreement, paving the way ...
... to receive funding for preclinical and clinical research projects ... ... ROCKLAND, Mass., Oct. 14 The Michael J. Fox Foundation,for ... five,research teams to speed development of effective therapies for the,under-addressed ...
... Logix, a privately held,biopharmaceutical company focused on using ... drugs, is pleased to announce the,appointment of Keith ... Chief,Executive Officer and to its Board of Directors. ... years of leadership experience in the,biotechnology industry., ...
Cached Biology Technology:Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 4Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 5Surface Logix Appoints Keith Dionne as President and Chief Executive Officer 2
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
Biology Products: